|

YL201 Clinical Trials

7 actively recruiting trials across 2 locations

Also known as: Platinum, Serplulimab

Pipeline

Phase 1: 2Phase 3: 2Phase 1/2: 3

Top Sponsors

  • MediLink Therapeutics (Suzhou) Co., Ltd.6
  • Amgen1

Indications

  • Cancer7
  • Small Cell Lung Cancer3
  • Lung Cancer3
  • Advanced Solid Tumors2
  • Recurrent or Metastatic Nasopharyngeal Carcinoma1

Other5 trials

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
Phase 1
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
Phase 3
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Phase 1/2
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Phase 1/2

Fair Oaks, California1 trial

A Study of YL201 in Patients With Advanced Solid Tumors

002

Phase 1/2

Irvine, California1 trial

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

City of Hope Orange County Lennar Foundation Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.